Preclinical CRO Service for Next Generation Probiotic Research based on Roseburia hominis
R. hominis and Diseases Services Platforms Products Background FAQs Resources
R. hominis for Disease Therapeutical Research
Scientists have investigated the mechanisms of R. hominis-host cross talk using both murine and in vitro models. In R. hominis, host intestinal colonization upregulated genes involved in conjugation/mobilization, metabolism, motility, and chemotaxis. In host cells, bacterial colonization upregulated genes associated with antimicrobial peptides, intestinal barrier function, toll-like receptor (TLR) signaling, and T-cell biology. Treatment with the R. hominis bacterium protected against DSS-induced colitis. These data reveal the immunomodulatory properties of R. hominis, suggesting a potential therapeutic benefit of R. hominis in the treatment of UC.
In addition to its impact on UC, R. hominis has been studied in the broader context of IBD. Notably, the administration of R. hominis in germ-free rats led to an increase in intestinal melatonin levels. Melatonin plays a critical role in regulating gut motility and immune responses. The study revealed that the metabolites of R. hominis, including propionate and butyrate, promote the synthesis of intestinal melatonin by increasing serotonin (5-HT) levels and activating Aanat transcription via p-CREB signaling. These findings present a compelling case for the therapeutic application of R. hominis in gut diseases, particularly by targeting melatonin production and improving intestinal homeostasis.
Fig. 1 Potential mechanisms of R. hominis in intestinal melatonin synthesis.1
Immunomodulation and Gut Health
The ability of R. hominis to regulate the immune system has broad implications beyond gastrointestinal diseases. Research involving murine models has shown that R. hominis can induce specific gene expression patterns, influencing both bacterial and host cell responses. In bacterial cells, genes related to motility, metabolism, and chemotaxis were upregulated upon colonization of the host gut. Meanwhile, in host cells, genes related to TLR signaling and T-cell biology were activated, strengthening the intestinal barrier and promoting immune tolerance.
What Services Can We Provide for R. hominis?
Creative Biolabs offers a comprehensive range of services to support the discovery and development of R. hominis as a next-generation probiotic. By leveraging advanced microbial technologies, we facilitate the isolation, characterization, and analysis of R. hominis strains for therapeutic purposes, focusing on gut health and inflammation-related diseases. Researchers can benefit from specialized services such as microbial identification, purification, SCFA production analysis, and in vitro immune modulation tests. Additionally, biological safety tests and small-scale production ensure the high-quality development of R. hominis strains. With tailor-made solutions, we provide flexibility in research design, assisting in strain selection, metabolic analysis, and preclinical testing to guarantee the efficacy and safety of R. hominis products for research.
|
Service
|
Description
|
Significance to Research
|
|
Microbial Identification
|
Identification of R. hominis strains from complex gut microbiota samples.
|
Essential for isolating R. hominis strains with probiotic potential.
|
|
Microbial Purifying
|
Purification of isolated R. hominis strains for research and development.
|
Ensures high-purity R. hominis strains for further study and product development.
|
|
SCFA Production Analysis
|
Analysis of short-chain fatty acid production, including butyrate.
|
Key to evaluating the metabolic benefits of R. hominis.
|
|
In Vitro Tests of Immune System Modulation
|
Testing the effects of R. hominis on immune cells in vitro.
|
Crucial for assessing R. hominis' role in immune modulation and inflammation control.
|
|
Biological Safety Test
|
Safety testing of R. hominis strains for human use.
|
Ensures that R. hominis strains are safe for application in therapeutic research.
|
|
Small-scale Production
|
Pilot-scale manufacturing of R. hominis strains for research and development.
|
Provides material for preclinical studies or early-stage product formulation.
|
Advanced Technology Platforms for R. hominis
Creative Biolabs employs cutting-edge technological platforms to support research and development of R. hominis as a next-generation probiotic. These platforms enable precise identification, analysis, and testing of the probiotic properties of R. hominis strains.
-
High-Throughput Screening: We offer high-throughput screening capabilities to rapidly identify R. hominis strains with desirable probiotic characteristics. This includes screening for high butyrate production and immune-modulating effects.
-
Genomic and Metagenomic Sequencing: Using whole genome sequencing (WGS), 16S rRNA gene sequencing, and other genomic sequencing technologies, we provide comprehensive insights into the genetic makeup of R. hominis. This facilitates the identification of genes associated with probiotic activity, such as SCFA production and immune modulation.
-
In Vitro and In Vivo Testing: In vitro and in vivo platforms are available to evaluate the potential of R. hominis in disease models. For example, in vitro tests of immune system modulation allow researchers to assess how R. hominis affects immune cells, while in vivo animal models, such as those for colitis, are used to validate the bacterium's efficacy in reducing inflammation.
R. hominis Related Products at Creative Biolabs
We supply a variety of R. hominis strains of different preservation numbers as below. If you need other strains, please contact us.
-
Customized strain culture supernatant. (e.g., for animal research)
-
Customized strain lyophilized powder containing certain CFU. (e.g., for animal research)
|
CAT
|
Product Name
|
Product Overview
|
Price
|
|
LBSX-0522-GF46
|
Roseburia hominis; 16839
|
Roseburia hominis is anaerobic, Gram-negative or Gram-variable, slightly curved rod-shaped and motile. It was isolated from human feces.
|
Inquiry
|
Creative Biolabs' team is diverse, knowledgeable, and agile, with a solid leadership universally recognized in the world of LBP. With our effective tools, extensive knowledge, unwavering support, assuring our partner's projects go forward successfully. If you are interested in our R. hominis related products and services, please feel free to contact us for more.
Introduction of R. hominis
Roseburia hominis is a flagellated, anaerobic bacterium within the Lachnospiraceae family of the Firmicutes, first isolated from human fecal samples in the United Kingdom. This species plays a significant role in maintaining gut health by producing butyrate, a short-chain fatty acid (SCFA) essential for maintaining intestinal integrity and regulating inflammatory responses. As a slightly curved, rod-shaped, motile bacterium, R. hominis exhibits Gram-variable characteristics, with cell sizes ranging from 0.5-1.5 to 5.0 µm in length. The R. hominis has become the cornerstone of research in probiotic development, particularly in its role as a next-generation probiotic (NGP).
The depletion of R. hominis has been closely linked to dysbiosis in various gastrointestinal disorders, such as ulcerative colitis (UC) and inflammatory bowel disease (IBD). Numerous studies have demonstrated that individuals suffering from these conditions often present with lower levels of butyrate-producing bacteria, including R. hominis and Faecalibacterium prausnitzii. Given its beneficial role in butyrate production and its influence on host immunity, R. hominis has garnered attention for its therapeutic potential in gut health and its prospective role in next-generation probiotics.
FAQs
How does R. hominis contribute to immune system modulation?
R. hominis influences immune responses by promoting anti-inflammatory pathways and enhancing the production of antimicrobial peptides. Its ability to increase butyrate levels also supports T-cell differentiation and maintains intestinal immune homeostasis, which is important for studying inflammatory and autoimmune conditions.
How can R. hominis strains be customized for research purposes?
Creative Biolabs offers the customization of R. hominis strains for various research applications. Strains can be tailored for specific CFU counts or produced in different formulations such as lyophilized powders or culture supernatants. These options provide flexibility for conducting animal studies and in vitro assays.
What in vitro and in vivo models are used to assess the efficacy of R. hominis in research?
Creative Biolabs utilizes advanced in vitro assays and murine models to evaluate the probiotic potential of R. hominis. These models help assess its effects on gut barrier integrity, immune modulation, and metabolic pathways.
How does Creative Biolabs ensure the safety of R. hominis strains in research?
To guarantee the safety of R. hominis strains, Creative Biolabs conducts extensive biological safety testing, including antibiotic susceptibility tests, toxin production analysis, and immune system interaction assays. These rigorous tests help ensure the strains are safe and effective for use in preclinical studies.
Resources
Reference
-
Song, Lijin, et al. "Roseburia hominis increases intestinal melatonin level by activating p-CREB-AANAT pathway." Nutrients 14.1 (2021): 117. Distributed under Open Access license CC BY 4.0, without modification.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
